Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

AIMD

Ainos Inc

Jun 14 • 04:00PM ET

0.8800

Dollar change +0.0598
Percentage change 7.29	%

Healthcare • Medical Devices • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-3.16	Insider Own	54.44%	Shs Outstand	4.68M	Perf Week	9.97%
Market Cap	5.72M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	2.96M	Perf Month	-14.98%
Income	-14.56M	PEG	-	EPS next Q	-	Inst Own	1.29%	Short Float	3.04%	Perf Quarter	-27.27%
Sales	0.09M	P/S	63.56	EPS this Y	-	Inst Trans	-	Short Ratio	0.62	Perf Half Y	-67.35%
Book/sh	3.69	P/B	0.24	EPS next Y	-	ROA	-43.83%	Short Interest	0.09M	Perf Year	-75.21%
Cash/sh	0.16	P/C	5.55	EPS next 5Y	-	ROE	-52.95%	52W Range	0.77 - 6.10	Perf YTD	-57.07%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-3.59%	ROI	-58.15%	52W High	-85.57%	Beta	1.39
Dividend TTM	-	Quick Ratio	0.28	Sales past 5Y	768.29%	Gross Margin	-222.12%	52W Low	13.56%	ATR (14)	0.10
Dividend Ex-Date	-	Current Ratio	0.32	EPS Y/Y TTM	33.31%	Oper. Margin	-14439.70%	RSI (14)	45.47	Volatility	12.55% 11.00%
Employees	46	Debt/Eq	0.25	Sales Y/Y TTM	-97.31%	Profit Margin	-15547.98%	Recom	-	Target Price	-
Option/Short	No / No	LT Debt/Eq	0.10	EPS Q/Q	8.80%	Payout	-	Rel Volume	204.63	Prev Close	0.82
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-57.84%	Earnings	-	Avg Volume	143.86K	Price	0.88
SMA20	-5.17%	SMA50	-12.26%	SMA200	-54.91%	Trades		Volume	29,437,994	Change	7.29%

Jun-14-24 08:00AM	Ainos Unveils Critical Progress in Ainos Flora Clinical Trials and Next-Gen Plans Powered by NVIDIA CUDA (ACCESSWIRE) +7.29%
May-15-24 08:00AM	Ainos to Initiate Clinical Study of New Potential VELDONA-Based Animal Drug, Expanding VELDONA's Potential Market (ACCESSWIRE)
May-13-24 09:54PM	AIMD Stock Earnings: Ainos Reported Results for Q1 2024 (InvestorPlace)
04:10PM	Ainos Reports First Quarter 2024 Financial Results (ACCESSWIRE)
May-07-24 08:00AM	Ainos Raises $9 Million in Growth Capital with Existing Shareholder (ACCESSWIRE)
04:20PM	Loading…
Mar-08-24 04:20PM	Ainos Reports Full Year 2023 Financial Results (ACCESSWIRE) +83.04%
07:58AM	Why Is Ainos (AIMD) Stock Up 153% Today? (InvestorPlace)
Mar-04-24 08:22AM	Why Is Ainos (AIMD) Stock Up 57% Today? (InvestorPlace) +35.24%
Feb-08-24 08:35AM	Small-Cap Growth Virtual Investor Conference Presentations Now Available for Online Viewing (GlobeNewswire)
Feb-06-24 09:51AM	Small-Cap Growth Virtual Investor Conference Agenda Announced for February 7th, 2024 (GlobeNewswire) -7.81%
Feb-05-24 09:00AM	Ainos Submits Clinical Hold Complete Response to US FDA to Resolve the Deficiencies on Investigational New Drug Phase II Trial of its VELDONA Formulation Against Mild COVID-19 Symptoms (ACCESSWIRE)
Feb-01-24 08:35AM	Ainos, Inc. to Present at Small-Cap Growth Virtual Investor Conference February 7th (GlobeNewswire)
Jan-24-24 09:00AM	Ainos Announces $1.75 Million Follow-On Funding (ACCESSWIRE) -10.34%
Jan-05-24 08:08AM	Why Is Ainos (AIMD) Stock Up 157% Today? (InvestorPlace) +58.38%
Jan-02-24 09:00AM	Ainos Regains Compliance with Nasdaq Minimum Bid Price Requirement (ACCESSWIRE) -6.34%
09:00AM	Loading…
Dec-26-23 09:00AM	Ainos, Nisshinbo Micro Devices and Inabata Initiate Phase 2 of VOC Co-development Powered by AI Nose, Accelerating the Digitalization of Smell (ACCESSWIRE)
Dec-14-23 05:52AM	AIMD Stock Earnings: Ainos Reported Results for Q1 2023 (InvestorPlace)
Dec-12-23 08:00AM	Ainos, Inc. Announces Stock Consolidation (ACCESSWIRE)
Nov-28-23 08:30AM	Ainos Announces Successful Manufacturing of VELDONA GMP Clinical Batch by Swiss Pharmaceutical (ACCESSWIRE)
Nov-21-23 08:30AM	Ainos Announces Positive Data Reported from its Clinical Studies for VELDONA as Potential Treatment of Oral Warts in HIV-Seropositive Patients, an Orphan Drug Designated by the FDA (ACCESSWIRE)
Nov-09-23 04:30PM	Ainos Reports Third Quarter 2023 Financial Results (ACCESSWIRE)
Nov-06-23 08:00AM	Ainos Signs MoU for Contract Clinical Trials to Conduct Clinical Study of Potential New Animal Drug Based on VELDONA (ACCESSWIRE)
Sep-25-23 08:30AM	Ainos Announces Placement of Initial $3 Million Tranche of $10 Million Private Placement (ACCESSWIRE)
Sep-19-23 12:26PM	With Orphan Drug Designation, Ainos' VELDONA Has Compelling Opportunity to Improve Quality of Life for HIV Patients (Newsfile)
Sep-18-23 07:00AM	Ainos VELDONA Granted Orphan Drug Designation by U.S. FDA for Potential Treatment of Oral Warts in HIV-Seropositive Patients (ACCESSWIRE) -21.30%
Sep-05-23 07:00AM	Ainos Commences Shipping its VELDONA Pet Cytoprotein Supplements in Taiwan (ACCESSWIRE)
Aug-15-23 01:29PM	Ainos, Inc - The AI Nose "Knows" What's Inside Your Body and Beyond (Newsfile)
Aug-11-23 04:30PM	Ainos Reports Second Quarter 2023 Financial Results (ACCESSWIRE)
Aug-10-23 08:00AM	Ainos Celebrates First Listing Anniversary on Nasdaq (ACCESSWIRE) -7.16%
Aug-09-23 08:00AM	Ainos Partners with Nisshinbo Micro Devices and Inabata to Co-Develop VOC Sensing Platform For Broader Industry Adoption (ACCESSWIRE) -6.49%
08:30AM	Loading…
Jun-27-23 08:30AM	Ainos Issues Mid-Year Business Update Letter to Shareholders (ACCESSWIRE)
Jun-20-23 08:30AM	Ainos Provides Insights Into Its AI Nose Technology (ACCESSWIRE) -7.97%
Jun-14-23 09:00AM	Ainos Completes VELDONA Pet Line-Up by Launching New VELDONA Pet Shiny and Slim in Push Towards $20M Revenue Target (ACCESSWIRE)
Jun-07-23 09:00AM	Ainos Launches New VELDONA Pet Lohas and Soothing Health Supplements, Catalyzing Its Drive to $20M Sales Target (ACCESSWIRE) +5.20%
May-30-23 09:00AM	Ainos Launches VELDONA Pet Cytoprotein Health Supplement Targeting $20M in Sales (ACCESSWIRE)
May-17-23 04:30PM	Ainos Appoints Amanda Sung as New Chief Financial Officer (ACCESSWIRE) -5.14%
May-12-23 04:15PM	Ainos Reports First Quarter 2023 Financial Results (ACCESSWIRE)
Mar-31-23 05:50PM	Ainos Reports Fourth Quarter and Full Year 2022 Financial Results (ACCESSWIRE)
Mar-21-23 07:00AM	Ainos Signs Agreement Establishing Topmed as Exclusive Distributor of VELDONA Animal Health Supplements in Taiwan (ACCESSWIRE) -16.13%
Mar-14-23 07:00AM	Ainos and Merdury Sign MoU to Explore Phase 3 Study of VELDONA Drug Candidate for Treatment of Oral Warts in HIV-Seropositive Patients (ACCESSWIRE) +79.17%
Mar-13-23 04:30PM	Ainos Announces US$3 Million Convertible Notes Private Placement (ACCESSWIRE) +5.88%
Jan-23-23 07:00AM	Ainos and Tah-An Sign MoU to Explore Manufacture of VELDONA Animal Investigational New Drug (ACCESSWIRE) -7.42%
Jan-17-23 07:00AM	Ainos Issues 2023 Shareholder Letter (ACCESSWIRE)
Nov-21-22 05:30AM	Ainos Publishes Preclinical Data Demonstrating its VELDONA Formulation's Potential as Treatment Candidates for the Most Common Medical Conditions for Companion Animals (PR Newswire) -15.75%
Nov-07-22 07:30AM	Ainos Reports Unaudited Third Quarter 2022 Financial Results (PR Newswire)
Nov-03-22 07:00AM	Five New Drug Candidates Show Promise as Ainos Pursues Licensing Partners of its Low-dose Oral Interferon Formulation (PR Newswire)
Oct-31-22 07:00AM	Ainos Pursues Licensing Partners to Accelerate Five Candidates of its Low-dose Oral Interferon Formulation VELDONA to Phase 3 Trials and Commercialization (ACCESSWIRE) -5.00%
Sep-30-22 07:00AM	Ainos Announces Positive Results from Additional Preclinical Study of Its Low-dose Oral Interferon Formulation Against New Variant Virus - Omicron (ACCESSWIRE) +36.96%
Aug-24-22 07:00AM	Ainos Submits Investigational New Drug Application to the U.S. FDA to Conduct Phase 2 Trial of its VELDONA Low-dose Oral Interferon Formulation Against Mild COVID-19 Symptoms (ACCESSWIRE)
Aug-17-22 08:05AM	Ainos Announces Master Services Agreement with Swiss Pharmaceutical, Ltd. for Drug Testing, Manufacturing, and Packaging for its VELDONA Product Candidates (ACCESSWIRE)
Aug-15-22 07:20AM	Ainos Reports Second Quarter 2022 Financial Results (ACCESSWIRE) -9.75%
Aug-11-22 02:12PM	Ainos Announces Closing of $3.3 Million Public Offering, Uplisting to NASDAQ, and Reverse Stock Split (ACCESSWIRE) -15.12%
Aug-10-22 09:20AM	How Much Of Ainos, Inc. (NASDAQ:AIMD) Do Insiders Own? (Simply Wall St.) -11.48%
Aug-08-22 08:57PM	Ainos Announces Pricing of $3.3 Million Public Offering, Uplisting to NASDAQ, and Reverse Stock Split (ACCESSWIRE)
Jun-27-22 07:00AM	Ainos Announces Positive Results from Preclinical Studies of Its Low-dose Oral Interferon Formulation Against COVID-19 (PR Newswire)
Jun-21-22 07:00AM	Ainos COVID-19 Antigen Self-Test Receives Approval for Sale in Taiwan (ACCESSWIRE) -39.44%
Dec-07-21 06:55PM	Ainos Announces Strategic Relationship with InnoPharmax to Jointly Develop Combined Oral Therapy for Coronavirus Infection (ACCESSWIRE)
Nov-03-21 12:00PM	Ainos SRNA Research Initiative Announces Milestones for mRNA Vaccine Development (ACCESSWIRE)
Aug-16-21 09:23AM	Ainos Elects Ms. Hui-Lan (Celia) Wu as CFO, Lawrence K. Lin as Executive Vice President of Operations, and Other Key Executives (ACCESSWIRE) -5.26%

Ainos, Inc. is a diversified medtech company, which engages in the development of medical technologies for point-of-care testing and safe and novel medical treatment for a broad range of disease indications. Its medtech solutions include COVID-19 Antigen Rapid Test Kit, VOC POCT-Ainos Flora, VOC POCT-Ainos Pen, VOC POCT-CHS430, Very Low-Dose Oral Interferon Alpha, and Synthetic RNA. The company was founded on June 26, 1984 and is headquartered in San Diego, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AIMD

Ainos Inc

Upgrade your FINVIZ experience